RegeneRx Biopharmaceuticals Stock Price, News & Analysis (OTCMKTS:RGRX)

$0.22 +0.01 (+4.76 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$0.22
Today's Range$0.21 - $0.22
52-Week Range$0.14 - $0.38
Volume30,270 shs
Average Volume77,702 shs
Market Capitalization$23.06 million
P/E Ratio-22.00
Dividend YieldN/A
Beta-2.17

About RegeneRx Biopharmaceuticals (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals logoRegeneRx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company's segment is the development and marketing of product candidates based on Tb4, an amino acid peptide. The Company has formulated Tb4 into three product candidates in clinical development: RGN-259, RGN-352 and RGN-137. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptide that is originally isolated from bovine thymus glands. RGN-259 is its preservative-free eye drop formulation of Tb4. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration. RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.

Receive RGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RGRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Other
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RGRX
CUSIPN/A
Phone301-208-9191

Debt

Debt-to-Equity Ratio-0.10%
Current Ratio0.30%
Quick Ratio0.30%

Price-To-Earnings

Trailing P/E Ratio-22
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$90,000.00
Price / Sales268.38
Cash Flow$0.00 per share
Price / Cash96.53
Book Value($0.06) per share
Price / Book-3.67

Profitability

Trailing EPS($0.01)
Net Income$220,000.00
Net Margins-1,539.62%
Return on Equity-23.23%
Return on Assets-170.89%

Miscellaneous

Employees12
Outstanding Shares109,790,000

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Frequently Asked Questions

What is RegeneRx Biopharmaceuticals' stock symbol?

RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX."

When will RegeneRx Biopharmaceuticals make its next earnings announcement?

RegeneRx Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April, 4th 2018. View Earnings Estimates for RegeneRx Biopharmaceuticals.

Where is RegeneRx Biopharmaceuticals' stock going? Where will RegeneRx Biopharmaceuticals' stock price be in 2018?

1 equities research analysts have issued 1 year price targets for RegeneRx Biopharmaceuticals' shares. Their predictions range from $1.50 to $1.50. On average, they anticipate RegeneRx Biopharmaceuticals' stock price to reach $1.50 in the next twelve months. View Analyst Ratings for RegeneRx Biopharmaceuticals.

Who are some of RegeneRx Biopharmaceuticals' key competitors?

Who are RegeneRx Biopharmaceuticals' key executives?

RegeneRx Biopharmaceuticals' management team includes the folowing people:

  • Allan L. Goldstein Ph.D., Chairman of the Board, Chief Scientific Advisor
  • J. J. Finkelstein, President, Chief Executive Officer
  • Mauro Bove, Independent Director
  • Raymond Donald Elsey, Independent Director
  • Joseph C. McNay, Independent Director

How do I buy RegeneRx Biopharmaceuticals stock?

Shares of RegeneRx Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RegeneRx Biopharmaceuticals' stock price today?

One share of RegeneRx Biopharmaceuticals stock can currently be purchased for approximately $0.22.

How big of a company is RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals has a market capitalization of $23.06 million and generates $90,000.00 in revenue each year. The biopharmaceutical company earns $220,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. RegeneRx Biopharmaceuticals employs 12 workers across the globe.

How can I contact RegeneRx Biopharmaceuticals?

RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The biopharmaceutical company can be reached via phone at 301-208-9191 or via email at [email protected].com.


MarketBeat Community Rating for RegeneRx Biopharmaceuticals (RGRX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about RegeneRx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.50$1.50$1.50$2.00
Price Target Upside: 455.56% upside455.56% upside455.56% upside589.66% upside

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Consensus Price Target History

Price Target History for RegeneRx Biopharmaceuticals (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/1/2017HC WainwrightLower Price TargetBuy$2.00 -> $1.50View Rating Details
5/10/2016Rodman & RenshawReiterated RatingBuyView Rating Details
(Data available from 2/17/2016 forward)

Earnings

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Earnings History and Estimates Chart

Earnings by Quarter for RegeneRx Biopharmaceuticals (OTCMKTS:RGRX)

RegeneRx Biopharmaceuticals (OTCMKTS RGRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/4/2018        
11/14/2017Q3 2017($0.01)ViewN/AView Earnings Details
11/14/2016Q3 2016$0.01ViewN/AView Earnings Details
5/16/2016Q1 2016($0.03)ViewN/AView Earnings Details
11/13/2015Q3 2015($0.01)ViewN/AView Earnings Details
8/14/2015Q2 2015($0.02)ViewN/AView Earnings Details
5/15/2015Q1 2015($0.02)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.02)($0.03)ViewN/AView Earnings Details
8/5/2011Q2 2011($0.02)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.02)($0.02)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.05)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.06)ViewN/AView Earnings Details
3/28/2008Q4 2007($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for RegeneRx Biopharmaceuticals (OTCMKTS:RGRX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RegeneRx Biopharmaceuticals (OTCMKTS RGRX)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

RegeneRx Biopharmaceuticals (OTCMKTS RGRX) News Headlines

Source:
DateHeadline
RegeneRx Receives Canadian Patent for Treating Neurological Injury and DamageRegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage
finance.yahoo.com - February 14 at 9:52 AM
RegeneRx Biopharmaceuticals (RGRX) and Alexza Pharmaceuticals (ALXA) Head to Head ContrastRegeneRx Biopharmaceuticals (RGRX) and Alexza Pharmaceuticals (ALXA) Head to Head Contrast
www.americanbankingnews.com - December 18 at 11:36 PM
Critical Review: RegeneRx Biopharmaceuticals (RGRX) & Alexza Pharmaceuticals (ALXA)Critical Review: RegeneRx Biopharmaceuticals (RGRX) & Alexza Pharmaceuticals (ALXA)
www.americanbankingnews.com - December 18 at 9:22 PM
Head-To-Head Comparison: RegeneRx Biopharmaceuticals (RGRX) and Endo International (ENDP)Head-To-Head Comparison: RegeneRx Biopharmaceuticals (RGRX) and Endo International (ENDP)
www.americanbankingnews.com - December 15 at 9:14 AM
Head to Head Analysis: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)Head to Head Analysis: Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - December 14 at 7:16 AM
Endo International (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX) Head-To-Head ContrastEndo International (ENDP) vs. RegeneRx Biopharmaceuticals (RGRX) Head-To-Head Contrast
www.americanbankingnews.com - December 13 at 1:34 PM
Head-To-Head Review: RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP)Head-To-Head Review: RegeneRx Biopharmaceuticals (RGRX) & Endo International (ENDP)
www.americanbankingnews.com - December 13 at 7:52 AM
RegeneRx Biopharmaceuticals (RGRX) vs. Alexza Pharmaceuticals (ALXA) Critical AnalysisRegeneRx Biopharmaceuticals (RGRX) vs. Alexza Pharmaceuticals (ALXA) Critical Analysis
www.americanbankingnews.com - December 10 at 5:22 AM
RegeneRx Releases Annual Letter to ShareholdersRegeneRx Releases Annual Letter to Shareholders
finance.yahoo.com - December 7 at 4:03 PM
Contrasting Alexza Pharmaceuticals (ALXA) and RegeneRx Biopharmaceuticals (RGRX)Contrasting Alexza Pharmaceuticals (ALXA) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 30 at 9:58 PM
RegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP) Critical ContrastRegeneRx Biopharmaceuticals (RGRX) versus Endo International (ENDP) Critical Contrast
www.americanbankingnews.com - November 29 at 9:44 PM
RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017RegeneRx Biopharmaceuticals, Inc. :RGRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 8:49 AM
Biodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX) Head to Head SurveyBiodel (ALBO) and RegeneRx Biopharmaceuticals (RGRX) Head to Head Survey
www.americanbankingnews.com - November 23 at 9:32 AM
Financial Comparison: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)Financial Comparison: RegeneRx Biopharmaceuticals (RGRX) and Biodel (ALBO)
www.americanbankingnews.com - November 23 at 3:12 AM
Financial Contrast: Alexza Pharmaceuticals (ALXA) versus RegeneRx Biopharmaceuticals (RGRX)Financial Contrast: Alexza Pharmaceuticals (ALXA) versus RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 19 at 11:44 AM
Tβ4s Role in Treatment of Eye Diseases Showcased at 5th International Thymosin SymposiumTβ4's Role in Treatment of Eye Diseases Showcased at 5th International Thymosin Symposium
finance.yahoo.com - November 18 at 11:20 AM
Reviewing Endo International PLC (ENDP) and RegeneRx Biopharmaceuticals (RGRX)Reviewing Endo International PLC (ENDP) and RegeneRx Biopharmaceuticals (RGRX)
www.americanbankingnews.com - November 16 at 5:42 AM
RegeneRx JV Announces Results of ARISE-2 Dry Eye TrialRegeneRx JV Announces Results of ARISE-2 Dry Eye Trial
finance.yahoo.com - October 31 at 8:36 AM
RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and AustraliaRegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia
finance.yahoo.com - August 31 at 9:24 AM
RegeneRx Collaborators Receive Notice of Intent to Grant EU Patent for the Treatment of Peripheral NeuropathyRegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy
finance.yahoo.com - August 15 at 6:43 AM
RegeneRx Updates on RGN-259 Phase 3 Dry Eye TrialRegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial
finance.yahoo.com - July 28 at 7:16 AM
Report: Sheriff Clarke Plagiarized Parts Of Thesis On Homeland SecurityReport: Sheriff Clarke Plagiarized Parts Of Thesis On Homeland Security
www.huffingtonpost.com - May 21 at 12:03 AM
Heres Why Democrats Are Not Storming The Gates, Demanding ImpeachmentHere's Why Democrats Are Not Storming The Gates, Demanding Impeachment
www.huffingtonpost.com - May 18 at 10:38 AM
OPEC Loses Power of Surprise as Majority Back Cuts ExtensionOPEC Loses Power of Surprise as Majority Back Cuts Extension
www.bloomberg.com - May 18 at 10:38 AM
Jury Acquits Tulsa Officer Betty Shelby in Shooting Death of Terence CrutcherJury Acquits Tulsa Officer Betty Shelby in Shooting Death of Terence Crutcher
www.nbcnews.com - May 18 at 10:38 AM
House Dems Smash Fundraising Records Ahead of MidtermsHouse Dems Smash Fundraising Records Ahead of Midterms
www.nbcnews.com - May 18 at 10:38 AM
Trump responds to special counsel, calls Russia probe single greatest witch huntTrump responds to special counsel, calls Russia probe 'single greatest witch hunt'
abcnews.go.com - May 18 at 10:38 AM
El-Sisi Pledges More Aid as Egypts Poor Struggle With InflationEl-Sisi Pledges More Aid as Egypt's Poor Struggle With Inflation
www.bloomberg.com - May 17 at 5:31 AM
Apple Supplier AAC Falls as Short Seller Gotham Questions ProfitApple Supplier AAC Falls as Short Seller Gotham Questions Profit
www.bloomberg.com - May 11 at 12:44 AM
Minnesota Health Officials Seek $5 Million for Measles OutbreakMinnesota Health Officials Seek $5 Million for Measles Outbreak
www.nbcnews.com - May 10 at 7:44 PM
Michael Kors Faces Tougher Market After Coach-Kate Spade MergerMichael Kors Faces Tougher Market After Coach-Kate Spade Merger
www.bloomberg.com - May 10 at 11:14 AM
Illegal border crossings continue to drop, even as Trump ramps up anti-immigration enforcementIllegal border crossings continue to drop, even as Trump ramps up anti-immigration enforcement
www.usatoday.com - May 9 at 7:04 PM
Officials on alert after tunnel collapse at Washington nuclear waste siteOfficials on alert after tunnel collapse at Washington nuclear waste site
www.latimes.com - May 9 at 7:04 PM
US warplanes among those barred from flying over Syrias safe zones in proposalUS warplanes among those barred from flying over Syria's 'safe zones' in proposal
www.foxnews.com - May 5 at 8:16 AM
US Air Force jets intercept Russian bombers, fighter jets near AlaskaUS Air Force jets intercept Russian bombers, fighter jets near Alaska
www.foxnews.com - May 4 at 8:47 AM
Warren: After Trump, ‘I Wonder If America Will Ever Be Ready for a Male President Again’Warren: After Trump, ‘I Wonder If America Will Ever Be Ready for a Male President Again’
www.nbcnews.com - May 4 at 12:27 AM
Susan Rice wont testify before Senate on Russia hacking, unmaskingSusan Rice won't testify before Senate on Russia hacking, 'unmasking'
www.foxnews.com - May 4 at 12:27 AM
Alton Sterling Shooting: Justice Department Announces No Federal ChargesAlton Sterling Shooting: Justice Department Announces No Federal Charges
www.nbcnews.com - May 3 at 7:26 PM
Tearful Jimmy Kimmel Breaks Down Revealing Newborn Sons Heart SurgeryTearful Jimmy Kimmel Breaks Down Revealing Newborn Son's Heart Surgery
www.huffingtonpost.com - May 2 at 5:21 PM
Merkel sees EU, Gulf states making progress on free trade deal Merkel sees EU, Gulf states making progress on free trade deal
www.reuters.com - May 1 at 10:20 AM
U.S. consumer spending unchanged in March; inflation subsides U.S. consumer spending unchanged in March; inflation subsides
www.reuters.com - May 1 at 10:20 AM
Los Angeles shooting spree: At least 1 killed, 3 hurt as police hunt suspects Los Angeles shooting spree: At least 1 killed, 3 hurt as police hunt suspects
www.foxnews.com - April 30 at 12:55 AM
Off target in 2016, global elite regroup at Milken conference Off target in 2016, global elite regroup at Milken conference
www.reuters.com - April 30 at 12:55 AM
At the Center of a Lawsuit, Uber’s Self-Driving Car Boss Takes Back SeatAt the Center of a Lawsuit, Uber’s Self-Driving Car Boss Takes Back Seat
www.nbcnews.com - April 28 at 8:04 AM
GM Truck and SUV Buildup Drives Profit as Plant Shutdowns LoomGM Truck and SUV Buildup Drives Profit as Plant Shutdowns Loom
www.bloomberg.com - April 28 at 8:04 AM
He tried to cool a citys anger, only to watch helplessly as it burned during the 1992 riotsHe tried to cool a city's anger, only to watch helplessly as it burned during the 1992 riots
www.latimes.com - April 28 at 8:04 AM
In 100 Days, Donald Trump Hasn’t Done Much Except Show Off His SignatureIn 100 Days, Donald Trump Hasn’t Done Much Except Show Off His Signature
www.huffingtonpost.com - April 28 at 8:04 AM
Delaware standoff with suspect in troopers killing reportedly overDelaware standoff with suspect in trooper's killing reportedly over
www.foxnews.com - April 27 at 10:54 AM
Delta passenger kicked off flight after bathroom emergencyDelta passenger kicked off flight after bathroom emergency
abcnews.go.com - April 27 at 10:54 AM
Will Trump’s Border Wall Prevent Human Trafficking? Experts Aren’t SureWill Trump’s Border Wall Prevent Human Trafficking? Experts Aren’t Sure
www.nbcnews.com - April 26 at 5:46 PM

SEC Filings

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

RegeneRx Biopharmaceuticals (OTCMKTS RGRX) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.